Special Update Meeting: The latest on cell replacement therapies for Parkinson's - watch again
Cure Parkinson’s held a special patient-focused event on Thursday 15 May 2025, which offered a unique opportunity for participants to engage with researchers in this field. Cure Parkinson’s supported the 2025 G-Force PD meeting, an international consortium dedicated to advancing cell replacement therapies for Parkinson’s....
Learn more
DAPA-PD: Dapansutrile for Parkinson’s
DAPA-PD is a phase 2 clinical trial of dapansutrile – a novel anti-inflammatory drug – to determine whether it may be able to slow Parkinson’s progression. Contents About the study Led by Dr Caroline Williams-Gray at Cambridge University, DAPA-PD will recruit 36 people with Parkinson’s....
Exenatide-PD3: Exenatide and Parkinson’s
The Exenatide-PD3 study was a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon) which finished in early 2024. The results of this trial have now been published and they indicate that the study did not slow the progression of Parkinson’s compared to...
ASPro-PD: Ambroxol and Parkinson’s
ASPro-PD, or Ambroxol to Slow Progression in Parkinson’s, is a phase 3 clinical trial looking to assess whether ambroxol, a cough medicine, can slow or stop the progression of Parkinson’s motor symptoms. Contents About the study Led by Professor Anthony Schapira at University College London...
The UP Study: UDCA and Parkinson’s
The UP Study, or UDCA for Parkinson’s Study, was a phase 2 clinical trial which aimed to assess the safety and tolerability of ursodeoxycholic acid (UDCA) in people with Parkinson’s. Contents About the study Led by Professor Oliver Bandmann at the University of Sheffield, this...